Sesen’s corporate spin amounts to nothing
According to Sesen Bio Vicineum was a shoo-in for US approval this month. What went so badly wrong?
Drug rejections hold steady in 2020
Concerns about a rise in complete response letters in 2020 come to naught, but this might not reassure drug developers.
